MENU
+Compare
HLN
Stock ticker: NYSE
AS OF
Feb 3 closing price
Price
$10.49
Change
+$1.47 (+16.30%)
Capitalization
46.6B

HLN stock forecast, quote, news & analysis

Haleon is one of the largest consumer health companies in the world... Show more

HLN
Daily Signal:
Gain/Loss:
A.I.Advisor
published price charts
These past five trading days, the stock lost 0.00% with an average daily volume of 0 shares traded.The stock tracked a drawdown of 0% for this period. HLN showed earnings on October 30, 2025. You can read more about the earnings report here.
Interact to see
Advertisement
A.I.Advisor
a Summary for HLN with price predictions
Feb 03, 2026

HLN's MACD Histogram just turned positive

The Moving Average Convergence Divergence (MACD) for HLN turned positive on January 22, 2026. Looking at past instances where HLN's MACD turned positive, the stock continued to rise in of 28 cases over the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on January 22, 2026. You may want to consider a long position or call options on HLN as a result. In of 63 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The 50-day moving average for HLN moved above the 200-day moving average on January 29, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where HLN advanced for three days, in of 222 cases, the price rose further within the following month. The odds of a continued upward trend are .

HLN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

The Aroon Indicator entered an Uptrend today. In of 222 cases where HLN Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The 10-day RSI Indicator for HLN moved out of overbought territory on January 07, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 21 similar instances where the indicator moved out of overbought territory. In of the 21 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 8 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where HLN declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.143) is normal, around the industry mean (29.792). P/E Ratio (22.972) is within average values for comparable stocks, (74.095). Projected Growth (PEG Ratio) (2.997) is also within normal values, averaging (2.035). Dividend Yield (0.018) settles around the average of (0.029) among similar stocks. P/S Ratio (3.170) is also within normal values, averaging (116.680).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. HLN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. HLN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 90, placing this stock worse than average.

A.I.Advisor
published Dividends

HLN paid dividends on September 18, 2025

Haleon plc HLN Stock Dividends
А dividend of $0.06 per share was paid with a record date of September 18, 2025, and an ex-dividend date of August 15, 2025. Read more...
A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are ZOETIS (NYSE:ZTS), Teva Pharmaceutical Industries Limited (NYSE:TEVA), Elanco Animal Health (NYSE:ELAN), Avadel Pharmaceuticals plc (NASDAQ:AVDL), Bausch Health Companies (NYSE:BHC), BioCryst Pharmaceuticals (NASDAQ:BCRX), Tilray Brands Inc. (NASDAQ:TLRY), Canopy Growth Corp (NASDAQ:CGC), Journey Medical Corp (NASDAQ:DERM), Aurora Cannabis (NASDAQ:ACB).

Industry description

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

Market Cap

The average market capitalization across the Pharmaceuticals: Generic Industry is 4.75B. The market cap for tickers in the group ranges from 2.12K to 64.79B. MKKGY holds the highest valuation in this group at 64.79B. The lowest valued company is CANQF at 2.12K.

High and low price notable news

The average weekly price growth across all stocks in the Pharmaceuticals: Generic Industry was -2%. For the same Industry, the average monthly price growth was -1%, and the average quarterly price growth was 14%. CABR experienced the highest price growth at 27%, while SXTC experienced the biggest fall at -70%.

Volume

The average weekly volume growth across all stocks in the Pharmaceuticals: Generic Industry was 18%. For the same stocks of the Industry, the average monthly volume growth was -24% and the average quarterly volume growth was -67%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 53
P/E Growth Rating: 63
Price Growth Rating: 58
SMR Rating: 80
Profit Risk Rating: 89
Seasonality Score: -19 (-100 ... +100)
View a ticker or compare two or three
HLN
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

Industry PharmaceuticalsGeneric

Profile
Fundamentals
Details
Industry
N/A
Address
The Heights
Phone
+44 1932822000
Employees
25408
Web
https://www.haleon.com